ALKS Alkermes plc

56.73
+0  (1%)
Previous Close 56.45
Open 56.57
Price To book 7.11
Market Cap 8.65B
Shares 152,547,000
Volume 429,555
Short Ratio 7.19
Av. Daily Volume 848,206

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Pivotal trials initiated December 2015 and February 2016. Four week efficacy data due YE 2017. Six month weight data mid-2018.
ALKS 3831 - ENLIGHTEN-2
Schizophrenia
CRL received March 15, 2010.
BYDUREON
Type 2 diabetes
Approved October 5 2015. sNDA filed for 2-month option August 8 2016. PDUFA date estimate June 8, 2017.
Aristada
Schizophrenia
Phase 3 trial to be initiated 2017 with data and NDA filing due 2018. BPC estimate of data mid-2018.
ALKS 8700
Multiple sclerosis (MS)
Phase 3 trial did not meet endpoint - February 2017.
ALKS 6428
Opioid dependence
Phase 3 data from first two trials did not meet their endpoints. FORWARD-5 data, the third of three trials did meet endpoints - October 2016. NDA to be filed 2017.
ALKS 5461
Major depressive disorder
Approved October 5 2015. sNDA filing due 2H 2016
Aristada
Schizophrenia
Pivotal trials initiated December 2015 and February 2016. Four week efficacy data due YE 2017. Six month weight data mid-2018.
ALKS 3831 - ENLIGHTEN-1
Schizophrenia

Latest News

  1. Alkermes to Host Conference Call to Discuss First Quarter 2017 Financial Results
  2. Alkermes Plc – Value Analysis (NASDAQ:ALKS) : April 13, 2017
  3. Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : April 12, 2017
  4. 5 Drug Stocks for Your Portfolio this World Health Day
  5. Drug Addiction Treatment Should Start in Emergency Room
  6. Acorda, Forward, Biogen Fall On Multiple Sclerosis Drug Fight
  7. 3 Top Biotech Stocks to Buy in April
  8. Vivitrol Offers Hope Against Opioid Addiction
  9. Alkermes to Present Preclinical Data on ALKS 4230 at the American Association for Cancer Research Annual Meeting
  10. Alkermes to Present Data on Two-Month Dosing Option Of ARISTADA® at 16th International Congress on Schizophrenia Research
  11. Alkermes Starts Phase III Study to Treat Multiple Sclerosis
  12. Alkermes Initiates Phase 3 Gastrointestinal Tolerability Study of ALKS 8700 for Treatment of Multiple Sclerosis
  13. Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : March 14, 2017
  14. The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
  15. Alkermes’ Corporate Presentation to be Webcast at the Barclays Global Healthcare Conference
  16. 4 Things Alkermes Wants Investors to Know
  17. Here’s What Mott Capital Management Thinks About Netflix, Alkermes, Vodafone & More
  18. Alkermes’ Corporate Presentation to be Webcast at the Cowen and Company 37th Annual Health Care Conference
  19. Drug Addiction Treatment Stocks to Watch
  20. Alkermes Plc :ALKS-US: Earnings Analysis: 2016 By the Numbers : February 17, 2017